Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Low-density lipoprotein receptor-related protein 1 85 kDa subunit: Cell membrane; Single-pass type I membrane protein. Membrane, coated pit.; SUBCELLULAR LOCATION: Low-density lipoprotein receptor-related protein 1 515 kDa subunit: Cell membrane; Peripheral membrane protein; Extracellular side. Membrane, coated pit.; SUBCELLULAR LOCATION: Low-density lipoprotein receptor-related protein 1 intracellular domain: Cytoplasm. Nucleus. Note=After cleavage, the intracellular domain (LRPICD) is detected both in the cytoplasm and in the nucleus. |
Domain |
PF12662 Complement Clr-like EGF-like PF16472 Domain of unknown function (DUF5050) PF07645 Calcium-binding EGF domain PF00057 Low-density lipoprotein receptor domain class A PF00058 Low-density lipoprotein receptor repeat class B |
Function |
Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission (PubMed:11907044, PubMed:12888553, PubMed:12713657). Acts as an alpha-2-macroglobulin receptor (PubMed:26142438). ; FUNCTION: (Microbial infection) Functions as a receptor for Pseudomonas aeruginosa exotoxin A. |
Biological Process |
GO:0001523 retinoid metabolic process GO:0006720 isoprenoid metabolic process GO:0006721 terpenoid metabolic process GO:0006869 lipid transport GO:0006898 receptor-mediated endocytosis GO:0006909 phagocytosis GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway GO:0007568 aging GO:0010517 regulation of phospholipase activity GO:0010640 regulation of platelet-derived growth factor receptor signaling pathway GO:0010642 negative regulation of platelet-derived growth factor receptor signaling pathway GO:0010715 regulation of extracellular matrix disassembly GO:0010721 negative regulation of cell development GO:0010874 regulation of cholesterol efflux GO:0010875 positive regulation of cholesterol efflux GO:0010876 lipid localization GO:0010975 regulation of neuron projection development GO:0010977 negative regulation of neuron projection development GO:0014812 muscle cell migration GO:0014909 smooth muscle cell migration GO:0014910 regulation of smooth muscle cell migration GO:0014912 negative regulation of smooth muscle cell migration GO:0015850 organic hydroxy compound transport GO:0015918 sterol transport GO:0016055 Wnt signaling pathway GO:0016101 diterpenoid metabolic process GO:0021537 telencephalon development GO:0021543 pallium development GO:0021987 cerebral cortex development GO:0022617 extracellular matrix disassembly GO:0030111 regulation of Wnt signaling pathway GO:0030178 negative regulation of Wnt signaling pathway GO:0030198 extracellular matrix organization GO:0030301 cholesterol transport GO:0030336 negative regulation of cell migration GO:0030900 forebrain development GO:0031345 negative regulation of cell projection organization GO:0032368 regulation of lipid transport GO:0032370 positive regulation of lipid transport GO:0032371 regulation of sterol transport GO:0032373 positive regulation of sterol transport GO:0032374 regulation of cholesterol transport GO:0032376 positive regulation of cholesterol transport GO:0032429 regulation of phospholipase A2 activity GO:0032956 regulation of actin cytoskeleton organization GO:0032970 regulation of actin filament-based process GO:0033344 cholesterol efflux GO:0035791 platelet-derived growth factor receptor-beta signaling pathway GO:0035904 aorta development GO:0035909 aorta morphogenesis GO:0040013 negative regulation of locomotion GO:0042157 lipoprotein metabolic process GO:0042953 lipoprotein transport GO:0043062 extracellular structure organization GO:0043277 apoptotic cell clearance GO:0043523 regulation of neuron apoptotic process GO:0043524 negative regulation of neuron apoptotic process GO:0044872 lipoprotein localization GO:0045665 negative regulation of neuron differentiation GO:0048008 platelet-derived growth factor receptor signaling pathway GO:0048514 blood vessel morphogenesis GO:0048844 artery morphogenesis GO:0050768 negative regulation of neurogenesis GO:0051222 positive regulation of protein transport GO:0051271 negative regulation of cellular component movement GO:0051402 neuron apoptotic process GO:0051493 regulation of cytoskeleton organization GO:0051961 negative regulation of nervous system development GO:0060191 regulation of lipase activity GO:0060840 artery development GO:0070997 neuron death GO:0097242 beta-amyloid clearance GO:0198738 cell-cell signaling by wnt GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1903053 regulation of extracellular matrix organization GO:1904951 positive regulation of establishment of protein localization GO:2000146 negative regulation of cell motility GO:2000586 regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 negative regulation of platelet-derived growth factor receptor-beta signaling pathway |
Molecular Function |
GO:0002020 protease binding GO:0005041 low-density lipoprotein receptor activity GO:0030228 lipoprotein particle receptor activity GO:0034185 apolipoprotein binding GO:0038024 cargo receptor activity GO:0042954 lipoprotein transporter activity GO:0070325 lipoprotein particle receptor binding |
Cellular Component |
GO:0005765 lysosomal membrane GO:0005905 clathrin-coated pit GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0030139 endocytic vesicle GO:0030425 dendrite GO:0030659 cytoplasmic vesicle membrane GO:0030666 endocytic vesicle membrane GO:0043025 neuronal cell body GO:0043235 receptor complex GO:0044297 cell body GO:0098589 membrane region GO:0098852 lytic vacuole membrane |
KEGG | - |
Reactome |
R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors R-HSA-1430728: Metabolism R-HSA-6806667: Metabolism of fat-soluble vitamins R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-975634: Retinoid metabolism and transport R-HSA-2168880: Scavenging of heme from plasma R-HSA-162582: Signal Transduction R-HSA-5653656: Vesicle-mediated transport R-HSA-2187338: Visual phototransduction |
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between LRP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between LRP1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of LRP1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of LRP1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of LRP1 in various data sets.
|
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRP1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of LRP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between LRP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | LRP1 |
Name | low density lipoprotein receptor-related protein 1 |
Aliases | CD91; LRP1A; APOER; A2MR; alpha-2-macroglobulin receptor; IGFBP3R; LRPA; TGFBR5; LRP-1; TbetaR-V/LRP-1/IGFBP ...... |
Chromosomal Location | 12q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting LRP1 collected from DrugBank database. |
Details on drugs targeting LRP1.
|